Type 2 Diabetes

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.

"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.

The glycemic gap was a stronger predictor of in-hospital mortality among adults with diabetes or hyperglycemia hospitalized for COVID-19.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

An analysis of data from the Canadian Longitudinal Study on Aging provides a snapshot of the apparent increase in risk of early menopause associated with a diagnosis of either type 1 diabetes or type 2 diabetes in aging women.

Both drug classes would improve type 2 diabetes outcomes as first-line agents, but costs would be need to be reduced by at least 70% to be considered cost-effective.

Greater psychological resilience was associated with lower BMI, fewer hospitalizations, and greater mental QOL in the T2D population.

An analysis of data from more than 9900 people with Down syndrome and 38,000 controls provides new insight into the apparent increase in risk of developing diabetes among children and young adults with Down syndrome.

A propensity-scored matched analysis is providing clinicians with new insight into the impact of age at diagnosis on risk of adverse health outcomes among people with diabetes.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

An analysis of more than 25,000 women with gestational diabetes from a 10-year period provides insight into the impact time to optimal glycemic control on risk of adverse perinatal outcomes, including risk of cesarean delivery, shoulder dystocia, LGA, and neonatal ICU admission.

In data published in the New England Journal of Medicine, the iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.

100 years after the discovery of insulin, the T1D Index may provide a foundational understanding of what steps need to be taken to both improve lives and reduce the incidence of T1D.

With the launch of the T1D index, the global burden of the disease and its impact is better understood. Dr. Kowalski joins to dig deeper into its importance and his personal connection to T1D.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

Announced on September 27, the latest guideline recommendations on diabetes management from the American Academy of Clinical Endocrinology represent their first update on the topic since 2015 and contains 170 new or updated evidence-based recommendations.

Dr. Craig Granowitz of Lexicon Pharmaceuticals details the success of the LX9211 clinical trial for painful diabetic neuropathy and the unique study design.

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!

A pair of studies published within days of one another provide insight into the apparent increase in risk of type 1 diabetes diagnoses following COVID-19, but one study purports this increase may not be the result of COVID-19.

Released on September 23, the consensus report from the American Diabetes Association and European Association for the Study of Diabetes outlines optimal strategies for management of hyperglycemia in type 2 diabetes—their first update on the subject since 2019.

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

Results of the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study provide insight into the comparative effectiveness of DPP-4 inhibitors, GLP-1 RAs, sulfonylureas, and insulin glargine for glycemic control and cardiovascular outcomes in people with type 2 diabetes.